Eagle Pharmaceuticals Agrees to Acquire Acacia Pharma Group plc

 

• Expects to add two U.S. Food and Drug Administration (“FDA”)-approved, new chemical entities (“NCEs”) with patent life into 2031 and expand acute care footprint
  

• Commercialized assets, BARHEMSYS® (amisulpride for injection) and BYFAVO® (remimazolam for injection), represent a strong strategic fit with Eagle’s specialized hospital-based salesforce

• Addressable market for the two products combined is estimated to be $3.1 billion per year1

• Anticipates significant financial synergies from the proposed transaction

• Company to hold investor conference call to discuss proposed transaction on Thursday, March 31, 2022, at 8:30am ET

https://finance.yahoo.com/news/eagle-pharmaceuticals-agrees-terms-acquire-080000597.html